Effectiveness of liposome bupivacaine for postoperative pain control in total knee arthroplasty: A PRISMA-compliant meta-analysis of randomized controlled trials

Zhan-Xia Yu, Zhao-Zhi Yang, Lu-Lan Yao, Zhan-Xia Yu, Zhao-Zhi Yang, Lu-Lan Yao

Abstract

Background: Adequate pain control after total knee arthroplasty (TKA) enables quicker recovery and reduces readmissions and treatment costs. The aim of this study was to determine the effect of liposomal bupivacaine (LB) for postoperative pain control in patients prepared for TKA.

Methods: We searched for the reports that evaluating the effect of liposomal bupivacaine for postoperative pain control in patients prepared for TKA between March 1983 and May 2017 in the electronic database Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, Web of Science, and Ovid. The main outcomes were visual analog scale (VAS) at 24, 48, and 72 hours. The secondary outcomes were total morphine consumption, the length of hospital stay, range of motion, and the occurrence of nausea.

Results: Seven randomized controlled trials (RCTs) enrolling 825 patients, with 413 in the LB group and 412 in the control group, were included in this meta-analysis. Our results suggested that administration LB was associated with a reduction of VAS by 4.22 points at 72 hours after TKA (WMD = -4.22, 95% CI -7.47, -0.97, P = .011) on a 100-point VAS. What's more, LB can decrease the occurrence of nausea when compared with traditional bupivacaine by 18.3% (risk ratio = 0.70, 95% confidence interval 0.55, 0.89, P = .003). LB was associated with an increase of the range of motion than traditional bupivacaine (P < .05). There was no significant difference between the VAS at 24, 48 hours, total morphine consumption and the length of hospital stay.

Conclusions: Administration with LB was associated with pain-relieving effects and reduces the morphine-related complications (nausea). Due the limited number of the included RCTs, large number and high quality RCTs are still need to identify the effects of LB for pain control after TKA.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The risk of bias summary for the included studies.
Figure 2
Figure 2
Forest plots comparing the occurrence of nausea between the 2 groups.
Figure 3
Figure 3
Scatter plot of the VAS at 24 hours (A), 48 hours (B), and 72 hours (C) and the dose of LB.

References

    1. Li F, Ma J, Kuang M, et al. The efficacy of pregabalin for the management of postoperative pain in primary total knee and hip arthroplasty: a meta-analysis. J Orthop Surg Res 2017;12:49.
    1. Rutherford RW, Jennings JM, Dennis DA. Enhancing recovery after total knee arthroplasty. Orthop Clin North Am 2017;48:391–400.
    1. Terkawi AS, Mavridis D, Sessler DI, et al. Pain management modalities after total knee arthroplasty: a network meta-analysis of 170 randomized controlled trials. Anesthesiology 2017;126:923–37.
    1. Karlsen AP, Wetterslev M, Hansen SE, et al. Postoperative pain treatment after total knee arthroplasty: a systematic review. PLoS One 2017;12:e0173107.
    1. Wheeler M, Oderda GM, Ashburn MA, et al. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain 2002;3:159–80.
    1. Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother 2007;41:400–6.
    1. Branney J, Izadpanah M. Liposomal bupivacaine peripheral nerve block for the management of postoperative pain. Nurs Stand 2017;31:42–3.
    1. Asche CV, Ren J, Kim M, et al. Local infiltration for postsurgical analgesia following total hip arthroplasty: a comparison of liposomal bupivacaine to traditional bupivacaine. Curr Med Res Opin 2017;1–8.
    1. Alijanipour P, Tan TL, Matthews CN, et al. Periarticular injection of liposomal bupivacaine offers no benefit over standard bupivacaine in total knee arthroplasty: a prospective, randomized controlled trial. J Arthroplasty 2017;32:628–34.
    1. Bramlett K, Onel E, Viscusi ER, et al. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee 2012;19:530–6.
    1. Collis PN, Hunter AM, Vaughn MD, et al. Periarticular injection after total knee arthroplasty using liposomal bupivacaine vs a modified ranawat suspension: a prospective, randomized study. J Arthroplasty 2016;31:633–6.
    1. Kuang MJ, Du Y, Ma JX, et al. The efficacy of liposomal bupivacaine using periarticular injection in total knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2017;32:1395–402.
    1. Wang X, Xiao L, Wang Z, et al. Comparison of peri-articular liposomal bupivacaine and standard bupivacaine for postsurgical analgesia in total knee arthroplasty: a systematic review and meta-analysis. Int J Surg 2017;39:238–48.
    1. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
    1. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363–74.
    1. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74.
    1. Wang C, Cai X-Z, Yan S-G. Comparison of periarticular multimodal drug injection and femoral nerve block for postoperative pain management in total knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2015;30:1281–6.
    1. GS HJ. Cochrane handbook for systematic reviews of interventions version 5.1.0[updated March 2011]. 2011.
    1. DeClaire JH, Aiello PM, Warritay OK, et al. Effectiveness of bupivacaine liposome injectable suspension for postoperative pain control in total knee arthroplasty: a prospective, randomized, double blind, controlled study. J Arthroplasty 2017;32:S268–71.
    1. Jain RK, Porat MD, Klingenstein GG, et al. The AAHKS clinical research award: liposomal bupivacaine and periarticular injection are not superior to single-shot intra-articular injection for pain control in total knee arthroplasty. J Arthroplasty 2016;31:22–5.
    1. Schroer WC, Diesfeld PG, LeMarr AR, et al. Does extended-release liposomal bupivacaine better control pain than bupivacaine after total knee arthroplasty (TKA)? A prospective, randomized clinical trial. J Arthroplasty 2015;30:64–7.
    1. Schwarzkopf R, Drexler M, Ma MW, et al. Is there a benefit for liposomal bupivacaine compared to a traditional periarticular injection in total knee arthroplasty patients with a history of chronic opioid use? J Arthroplasty 2016;31:1702–5.
    1. Hamilton TW, Athanassoglou V, Mellon S, et al. Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain. Cochrane Database Syst Rev 2017;2:CD011419.
    1. Wu ZQ, Min JK, Wang D, et al. Liposome bupivacaine for pain control after total knee arthroplasty: a meta-analysis. J Orthop Surg Res 2016;11:84.
    1. Ong JC, Chin PL, Fook-Chong SM, et al. Continuous infiltration of local anaesthetic following total knee arthroplasty. J Orthop Surg (Hong Kong) 2010;18:203–7.
    1. Sun XL, Zhao ZH, Ma JX, et al. Continuous local infiltration analgesia for pain control after total knee arthroplasty: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2015;94:e2005.
    1. Singh PM, Borle A, Trikha A, et al. Role of periarticular liposomal bupivacaine infiltration in patients undergoing total knee arthroplasty: a meta-analysis of comparative trials. J Arthroplasty 2017;32:675.e1–88.e1.
    1. Khlopas A, Elmallah RK, Chughtai M, et al. The learning curve associated with the administration of intra-articular liposomal bupivacaine for total knee arthroplasty: a pilot study. Surg Technol Int 2017;30:314–20.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다